Related content

Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial

By Stathopoulos G. P.   Katis C.   Tsavdaridis D.   Dimitroulis J.   Karaindros D.   Stathopoulos J.   Dimou E.  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 4, 2006-10 ,pp. : 555-560

Springer Publishing Company

Access to resources Recommend Favorite

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

By Wilop Stefan   Hobe Sabine   Crysandt Martina   Esser Albert   Osieka Rainhardt   Jost Edgar  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 10, 2009-10 ,pp. : 1429-1435

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer

By Xu N.   Shen P.   Zhang X.   Yu L.   Bao H.   Shi G.   Huang S.   Chen J.   Mou H.   Fang W.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 1-7

Springer Publishing Company

Access to resources Recommend Favorite

Japanese experience with second-line chemotherapy with low-dose (60 mg/m) docetaxel in patients with advanced non-small-cell lung cancer

By Mukohara Toru   Takeda Koji   Miyazaki Masaki   Takifuji Nobuhide   Terakawa Kazuhiko   Negoro Shunichi  

Cancer Chemotherapy and Pharmacology, Vol. 48, Iss. 5, 2001-11 ,pp. : 356-360

Springer Publishing Company

Access to resources Recommend Favorite

Afatinib in advanced non-small-cell lung cancer

By Di Maio Massimo   Gridelli Cesare   Grossi Francesco   Novello Silvia   de Marinis Filippo  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 493-504

Future Medicine

Access to resources Recommend Favorite